<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654391</url>
  </required_header>
  <id_info>
    <org_study_id>CS16098</org_study_id>
    <nct_id>NCT03654391</nct_id>
  </id_info>
  <brief_title>Study of Obesity Control by Astragalus and Notoginseng Extrats</brief_title>
  <official_title>Study of Obesity Control by Astragalus and Notoginseng Extrats</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chung Shan Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of the Astragalus and Notoginseng extrats on obesity control was demonstrated in
      a randomized double-blind, and crossover human trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity refers to the body due to physiological or biochemical function of the change caused
      by excessive accumulation of body fat, resulting in weight gain. Hence, the aim of this study
      was to evaluate the effects of the Astragalus and Notoginseng extrats on obesity control by a
      randomized double-blind and crossover human trial. Subjects with simple obesity (body mass
      index (BMI) ≥ 27 or body fat ≥ 30%) ingested 5 extrats (n = 19) capsules or placebo (n = 19)
      perday for 12 weeks of a stage. Anthropometric measurements (body weight, body fat, blood
      pressure) and blood biochemical markers including fasting blood glucose (FBG), albumin, total
      cholesterol (TC), triglyceride (TG), HDL-C, LDL-C, creatinine (Cr), blood urea nitrogen
      (BUN), AST, ALT were examined every six weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2016</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The changes of body weight and BMI of the subjects.</measure>
    <time_frame>12 weeks</time_frame>
    <description>values change of body weight and BMI between before to after 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The changes of triglyceride (TG) of the subjects</measure>
    <time_frame>12 weeks</time_frame>
    <description>values change of triglyceride (TG) between before to after 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>InnoSlim</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects ingested 2 capsules InnoSlim® (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects ingested 2 capsules placebo (Control group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>InnoSlim</intervention_name>
    <description>Subjects ingested 2 capsules (Experimental group) in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.</description>
    <arm_group_label>InnoSlim</arm_group_label>
    <other_name>Astragalus and Notoginseng extrats</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects ingested 2 capsules placebo in the morning and 3 capsules in the evening (5 capsules/d) for 12 weeks of a stage. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every six weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) ≥ 27 or body fat ≥ 30%;

          -  No history of serious diseases associated with heart, liver, kidney, endocrine systems
             or other organs;

          -  No drugs consumption.

        Exclusion Criteria:

          -  BMI &gt;35;

          -  Alcoholic;

          -  US-controlled diabetics;

          -  Stoke in past one year;

          -  High blood pressure;

          -  Mental diseases or melancholia;

          -  Pregency or breast-feeding a child.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>irb@csh.org.tw Mr Shen, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung Shan Medical University</affiliation>
  </overall_official>
  <results_reference>
    <citation>Chang W.L. et al. The inhibitory effect of ginse¬noside Rg1 on glucose and lipid production in human HepG2 cells. Adaptive Medicine. 2013, 5(4), 181-188.</citation>
  </results_reference>
  <results_reference>
    <citation>Chang TC, Huang SF, Yang TC, Chan FN, Lin HC, Chang WL. Effect of ginsenosides on glucose uptake in human Caco-2 cells is mediated through altered Na+/glucose cotransporter 1 expression. J Agric Food Chem. 2007 Mar 7;55(5):1993-8. Epub 2007 Feb 2.</citation>
    <PMID>17269785</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang CW, Su SC, Huang SF, Huang YC, Chan FN, Kuo YH, Hung MW, Lin HC, Chang WL, Chang TC. An Essential Role of cAMP Response Element Binding Protein in Ginsenoside Rg1-Mediated Inhibition of Na+/Glucose Cotransporter 1 Gene Expression. Mol Pharmacol. 2015 Dec;88(6):1072-83. doi: 10.1124/mol.114.097352. Epub 2015 Oct 1.</citation>
    <PMID>26429938</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>You-Cheng Shen</investigator_full_name>
    <investigator_title>School of Health Diet and Industry Managment</investigator_title>
  </responsible_party>
  <keyword>Astragalus and Notoginseng extrats</keyword>
  <keyword>Body weight</keyword>
  <keyword>BMI</keyword>
  <keyword>Triglyceride</keyword>
  <keyword>obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

